Á lódáil...
Brexanolone for the treatment of patients with postpartum depression
On March 19, 2019, the United States Food and Drug Administration (FDA) approved Zulresso (brexanolone) for intravenous use for the treatment of postpartum depression (PPD) in adult women. The decision was based on three recent clinical trials following an FDA priority review and breakthrough therap...
Na minha lista:
| Foilsithe in: | Drugs Today (Barc) |
|---|---|
| Main Authors: | , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
2019
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8033597/ https://ncbi.nlm.nih.gov/pubmed/31584571 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1358/dot.2019.55.9.3040864 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|